Literature DB >> 24462540

Diagnostic accuracy of physician and self-referred patients for thoracic outlet syndrome is excellent.

Kendall Likes1, Danielle H Rochlin2, Quinn Salditch2, Thadeus Dapash2, Yen Baker2, Roxanne DeGuzman2, Shalini Selvarajah2, Julie Ann Freischlag2.   

Abstract

BACKGROUND: The purpose of this study was to categorize patients referred to a specialized thoracic outlet syndrome (TOS) practice to determine the diagnostic accuracy of those who are physician and self-referred.
METHODS: Demographic and clinical data on all patients who were referred for TOS between 2006 and 2010 were retrospectively reviewed from a prospectively maintained institutional review board-approved database and patient records.
RESULTS: Between 2006 and 2010, 621 patients were referred for TOS (433 women and 188 men; mean age 39 years [range 10-87]). Five hundred seventy-one patients (92%) were diagnosed with TOS, with 421 (74%) neurogenic, 126 (22%) venous, and 24 (4%) arterial TOS cases. Of the 525 physician referrals, 478 (91%) had TOS, and of the 93 self-referrals, 90 (97%) had TOS. The 421 patients with neurogenic TOS (NTOS, 304 women and 117 men) had symptoms on average for 56 months (range 1-516). Two hundred seventy-one patients (64%) were initially treated with TOS-specific physical therapy (PT), and 100 (37%) improved. One hundred seventy-eight patients (42%) underwent a lidocaine block, and 145 patients (81%) had a positive block. Seventy-four patients (18%) underwent Botox injections 44 (60%) of which were positive and the average number of Botox injections was 1.3. One hundred forty patients (33%) underwent transaxillary first rib resection and scalenectomy (FRRS), and 128 patients (91%) improved. Of patients undergoing FRRS, 92 (66%) had a lidocaine block, 82 (89%) of which were positive. Of patients with a positive lidocaine block, 74 (90%) improved after FRRS. Of patients undergoing FRRS, 31 (22%) underwent Botox injections, 15 (48%) of which were positive. Of patients with a positive Botox block, 14 (93%) improved after FRRS. Average length of time between initial visit and operation was 6.4 months (range 2 weeks to 34 months), and average follow-up time was 13 months (range 1 week to 49 months).
CONCLUSIONS: 1) Both referring physicians and patients are very accurate in their preliminary diagnosis of TOS (neurogenic, venous, or arterial TOS). 2) In a specialized TOS practice, two-thirds of patients are sent to TOS-specific PT and one-third improve from this treatment alone. 3) One-third of patients referred for NTOS eventually undergo FRRS with a 91% success rate.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24462540     DOI: 10.1016/j.avsg.2013.12.011

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  5 in total

Review 1.  MRI of thoracic outlet syndrome in children.

Authors:  Govind B Chavhan; Vaishnavi Batmanabane; Prakash Muthusami; Alexander J Towbin; Gregory H Borschel
Journal:  Pediatr Radiol       Date:  2017-05-10

2.  A DECADE OF EXCELLENT OUTCOMES AFTER SURGICAL INTERVENTION: 538 PATIENTS WITH THORACIC OUTLET SYNDROME.

Authors:  Julie Ann Freischlag
Journal:  Trans Am Clin Climatol Assoc       Date:  2018

Review 3.  New Diagnostic and Treatment Modalities for Neurogenic Thoracic Outlet Syndrome.

Authors:  M Libby Weaver; Ying Wei Lum
Journal:  Diagnostics (Basel)       Date:  2017-05-27

4.  Microvascular Response to the Roos Test Has Excellent Feasibility and Good Reliability in Patients With Suspected Thoracic Outlet Syndrome.

Authors:  Samir Henni; Jeanne Hersant; Myriam Ammi; Fatima-Ezzahra Mortaki; Jean Picquet; Mathieu Feuilloy; Pierre Abraham
Journal:  Front Physiol       Date:  2019-02-21       Impact factor: 4.566

Review 5.  Thoracic Outlet Syndrome: Single Center Experience on Robotic Assisted First Rib Resection and Literature Review.

Authors:  Andreas Gkikas; Savvas Lampridis; Davide Patrini; Peter B Kestenholz; Luis Filipe Azenha; Gregor Jan Kocher; Marco Scarci; Fabrizio Minervini
Journal:  Front Surg       Date:  2022-03-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.